Navigation Links
EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
Date:7/14/2009

EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

London (PRWEB) July 14, 2009 -- EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.

The Habib™ EndoHPB is an endoscopic bipolar radiofrequency (RF) catheter that allows for:

1) Destruction of biliary tumours prior to stent insertion: Currently, endoscopic plastic stents become clogged by sludge or by tumour pressure narrowing the stent lumen, necessitating regular changing of the stent. Use of the Habib™ EndoHPB prior to stent insertion improves the stent patency by delaying tumour growth.

2) Clearance of obstructed metal stents: Self-expanding mesh metal stents (SEMS), which have longer patency and lower occlusion rates, are still subject to obstructive tumour in-growth. Since SEMS cannot be removed, the Habib™ EndoHPB can be used to ablate the occluding tissue.

"The EndoHPB significantly improves on the procedure for patients suffering from malignant biliary obstruction," stated EMcision's CEO, the internationally renowned surgeon, Professor Nagy Habib. "I am particularly excited about the EndoHPB's application in clearing obstructed metal stents, which represents a real innovation. As a surgeon, I prefer simple and elegant systems and I believe we have achieved that with the EndoHPB. Interventional radiologists and endoscopists who use it tell us they like its convenience and efficacy, and administrators look kindly on the fact that no capital expenditure is required."

The Habib™ EndoHPB is inserted by the interventional radiologist in cases of hilar cholangiocarcinoma or by the endoscopist for tumours in the lower bile duct and head of pancreas. It is a sterile, single-use device compatible with the most commonly used RF generators. The fifth in EMcision's line of medical devices, the EndoHPB is CE marked and has earned considerable positive feedback from its use in clinical settings throughout Europe.

The Company's first product, the Habib™ 4X™, captured close to 30% share of the US hepatic resection market following its introduction under exclusive license to AngioDynamics (NASDAQ: ANGIO). "We expect similar success with the EndoHPB," stated Prof. Habib.

EMcision seeks U.S. distributors to help with this product rollout.

About EMcision:
Founded in 2001 to develop and commercialize clinically relevant and cost-effective medical devices which enhance the quality of patient care, EMcision Limited has introduced a series of innovative proprietary medical devices based on proven RF technology. EMcision's founder, Chairman and CEO Prof. Nagy Habib is also Chair of Surgery and Head of Liver and Pancreatic Surgery at Imperial College London and Hammersmith Hospital. The Company is backed by a group of investors, including the Imperial College University Challenge Seed Fund.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2634994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Xanodyne Announces New Executive Team Members
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
3. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
4. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
5. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... are characterized by a wide range of overlapping clinical features. The advancement of ... in the field of NDD research and testing. , However, designing a ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Extreme Environment Shakers today. , Extreme Environment Shakers , ... for optimal cell growth such as cell cultures, solubility studies and extraction procedures. ...
(Date:7/14/2017)... Martinsried, Germany (PRWEB) , ... July 14, 2017 ... ... developed standardized solution for sample preparation of proteins to clean peptides for mass ... Bioruptor® sonication system. , The PreOmics iST Kit is based on proprietary ...
(Date:7/13/2017)... ... July 13, 2017 , ... Frederick’s first ... experienced robust growth in the past year after an intensive restructuring. Under the ... Acceleration Programs and expanded its board of directors to revitalize the organization. As ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):